RUNX3 Inactivation by Point Mutations and Aberrant DNA Methylation in Bladder Tumors
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
RUNX3 is inactivated at high frequency in many tumors. However, in most cases, inactivation is caused by silencing of the gene due to promoter hypermethylation. Because epigenetic silencing is known to affect many major tumor suppressor genes in cancer cells, it is not clear whether RUNX3 is primarily responsible for the induction of carcinogenesis in these cases, except for the gastric cancer cases that we reported previously. We investigated genetic and epigenetic alterations of RUNX3 in 124 bladder tumor cases and seven bladder tumor–derived cell lines. Here we show that RUNX3 is inactivated by aberrant DNA methylation in 73% (90 of 124) of primary bladder tumor specimens and 86% (six of seven) of bladder tumor cell lines. In contrast, the promoter regions of 20 normal bladder mucosae were unmethylated. Importantly, one patient bore missense mutations, each of which resulted in amino acid substitutions in the highly conserved Runt domain. The mutations abolished the DNA-binding ability of RUNX3. A second patient had a single nucleotide deletion within the Runt domain coding region that resulted in truncation of the protein. RUNX3 methylation was a significant risk factor for bladder tumor development, superficial bladder tumor recurrence, and subsequent tumor progression. These results strongly suggest that inactivation of RUNX3 may contribute to bladder tumor development and that promoter methylation and silencing of RUNX3 could be useful prognostic markers for both bladder tumor recurrence and progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation
Ducy, P., Zhang, R., Geoffroy, V., Ridall, A. L., & Karsenty, G. (1997) · Cell · doi:10.1016/s0092-8674(00)80257-3 · Cited by 4,246
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y.-H., Inada, M., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80258-5 · Cited by 4,244
Frommer, M., McDonald, L. E., Millar, D. S., Collis, C. M., Watt, F., Grigg, G. W., Molloy, P. L., & Paul, C. L. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.5.1827 · Cited by 3,238
Song, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100 · cited 1×
“For example, heterozygous loss-of-function mutation of RUNX3 is associated with familial platelet disorder with predisposition to acute myeloid leukemia (44).”
BackgroundOgawa, E., Inuzuka, M., Maruyama, M., Satake, M., Naito-Fujimoto, M., Ito, Y., & Shigesada, K. (1993) · Virology · doi:10.1006/viro.1993.1262 · Cited by 493
Self-citationWang, S., Wang, Q., Crute, B. E., Melnikova, I. N., Keller, S. R., & Speck, N. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.6.3324-3339.1993 · Cited by 435
The runt domain identifies a new family of heterometric transcriptional regulators
Kagoshima, H., Shigesada, K., Satake, M., Ito, Y., Miyoshi, H., Ohki, M., Pepling, M., & Gergen, P. (1993) · Trends in Genetics · doi:10.1016/0168-9525(93)90026-e · Cited by 326
Self-citationCloning, mapping and expression of PEBP2αC, a third gene encoding the mammalian Runt domain
Bae, S.-C., Takahashi, E.-I., Zhang, Y. W., Ogawa, E., Shigesada, K., Namba, Y., Satake, M., & Ito, Y. (1995) · Gene · doi:10.1016/0378-1119(95)00060-j · Cited by 158 · cited 1×
“The RUNX3 gene is located on human chromosome 1p36, a region that has long been suspected to harbor one or more suppressors of various tumors ( 30 ).”
BackgroundSelf-citation
Cited by
The RUNX family: developmental regulators in cancer
Ito, Y., Bae, S.-C., & Chuang, L. S. H. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3877 · Cited by 399
Self-citationGRØNBÆK, K., HOTHER, C., & JONES, P. A. (2007) · APMIS · doi:10.1111/j.1600-0463.2007.apm_636.xml.x · Cited by 366
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99002-8 · Cited by 203
Self-citationCovalent Modifications of RUNX Proteins: Structure Affects Function
Blumenthal, E., Greenblatt, S., Huang, G., Ando, K., Xu, Y., & Nimer, S. D. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-10-3233-2_3 · Cited by 16
Runx3 inhibits melanoma cell migration through regulation of cell shape change
Zhang, X., Wang, L., Zeng, X., Fujita, T., & Liu, W. (2017) · Cell Biology International · doi:10.1002/cbin.10824 · Cited by 9
“Previous studies have demonstrated that Runx3 functions as a tumor suppressor in many cancer types and inhibits cancer cell migration 1052 Cell Biol Int 41 (2017) 1048–1055 © 2017 International Federation of Cell Biology (Ito et al., 2005; Kim et al., 2005).”
Background
Metadata
- Authors
- Kim, W.-J., Kim, E.-J., Jeong, P., Quan, C., Kim, J., Li, Q.-L., Yang, J.-O., Ito, Y., & Bae, S.-C.
- Venue
- Cancer Research
- Published
- 2005-10-15
- Volume
- 65
- Issue
- 20
- Pages
- 9347-9354
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2141870702
- Cited by
- 144
- References
- 8
- FWCI
- 2.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RUNX3 Inactivation by Point Mutations and Aberrant DNA Methylation in Bladder Tumors. https://app.cochat.ai/papers/10.1158/0008-5472.can-05-1647
- The paper
- Kim, W.-J., Kim, E.-J., Jeong, P., Quan, C., Kim, J., Li, Q.-L., Yang, J.-O., Ito, Y., & Bae, S.-C. (2005). RUNX3 Inactivation by Point Mutations and Aberrant DNA Methylation in Bladder Tumors. Cancer Research. https://doi.org/10.1158/0008-5472.can-05-1647
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.